The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma
Abstract
PHEOCHROMOCYTOMAS (PHEO) (1–3) are catecholamine-producing tumors that arise from chromaffin cells. PHEO are mostly situated within the adrenal medulla, although in about 9–23% of cases, tumors develop from extraadrenal chromaffin tissue (adjacent to sympathetic ganglia of the neck, mediastinum, abdomen, and pelvis) and are often referred to as paragangliomas (4–6). PHEO situated in the adrenal gland are identified more commonly than those in extraadrenal tissues, because clinicians usually focus on the adrenal gland as a main source of catecholamine production. Although they usually choose a proper imaging technique to attempt the localization of PHEO in the adrenal gland, they are often confused as to which algorithm to follow and what technique to choose for the detection of extraadrenal PHEO. Furthermore, physicians often neglect the facts that up to approximately 25% of patients with apparent sporadic PHEO may, in fact, be carriers of germline mutations, indicating hereditary disease with a predisposition for extraadrenal, often multifocal, PHEO (7); that in children, multifocal and extraadrenal PHEO are found in up to 30–43% of cases (6, 8–12); that malignant PHEO account for up to 26–35% of cases (13–18); that the prevalence of malignancy in sporadic adrenal PHEO is 9% (5); and that about 10% of patients with PHEO present with metastatic disease at the time of their initial work-up (19). After initial failed surgery, patients with metastatic PHEO are commonly reevaluated using metaiodobenzylguanidine (MIBG) scintigraphy, a modality that should actually be performed before surgery to confirm that a tumor was indeed a PHEO (5–9% of the population harbor an adrenal tumor, most commonly a benign adenoma) (20–22) or to rule out metastatic disease. These patients are then reoperated upon, suffering additional surgery-related complications and substantial financial expenses. Some clinicians consider the presence of sporadic unilateral small PHEO as indicative of benign disease. This was concluded in older studies of series of patients with PHEO (23–25). However, more recent works from large series of patients with benign and malignant disease in the United States and Europe do not support this view; rather, they support the opinion that there are no absolute clinical, imaging, or laboratory criteria to predict malignancy and clinical course of PHEO (5, 16, 19, 26–32). Nevertheless, PHEO tumors with a diameter larger than 5 cm have a higher potential to metastasize, and such patients should be followed more frequently (33). Consequently, it seems that ruling out metastatic PHEO before initial surgery would be useful, because the detection of other lesions may dramatically affect treatment and follow-up. Localization of PHEO should be attempted using at least two imaging modalities. Anatomical imaging studies [computed tomography (CT) and magnetic resonance imaging (MRI)] should be combined with functional (nuclear medicine) imaging studies for optimal results to locate primary, recurrent, or metastatic PHEO. Functional imaging studies (enabled by the presence of the noradrenergic transporter system on PHEO cells) include [123I]- or [131I]MIBG scintigraphy, 6-[18F]fluorodopamine ([18F]DA), [18F]dihydroxyphenylalanine ([18F]DOPA), [11C]hydroxyephedrine, and [11C]epinephrine positron emission tomography (PET) (34–38). Chromaffin cells in various neuroendocrine tissues [such as PHEO, but also medullary thyroid carcinoma (MTC)] express the plasma membrane norepinephrine transporter and the intracellular vesicular monoamine transporter. The norepinephrine transporter is responsible for the cellular uptake of both MIBG (39) and [18F]DA (36). We have recently shown that [18F]DA PET scanning could theoretically represent yet another imaging modality for the detection of MTCs (40) because MTC cells often express the norepinephrine transporter and concentrate MIBG (41). In most cases, functional imaging modalities are either able to confirm that a tumor is a PHEO or can lead to further diagnostic work-up. For example, in a patient with positive plasma metanephrines and MIBG imaging studies showing uptake in extraadrenal locations, the possible presence of multiple endocrine neoplasia type 2 (MEN 2)-related tumors (including MTC) should be considered and assessed with measurement of serum calcitonin and/or RET mutations. Functional imaging studies are also very helpful to rule out metastatic disease in most cases. However, as malignant PHEO may undergo tumor dedifferentiation with loss of specific neurotransmitter transporters (Refs. 42 and 43 , and Pacak, K., unpublished observation), leading to the inability to accumulate these isotopes and consequent lack of localization, [18F]fluorodeoxyglucose ([18F]FDG) PET scanning or somatostatin receptor scintigraphy (Octreoscan) may be required as the next step of the imaging algorithm. [18F]FDG is a nonspecific imaging agent whose accumulation is based on the higher metabolic
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Oei, H. Y., van Hagen, M., Postema, P. T. E., de Jong, M., Reubi, J. C., et al. (1993) · European Journal of Nuclear Medicine · doi:10.1007/bf00181765 · Cited by 1,564
Germ-Line Mutations in Nonsyndromic Pheochromocytoma
Neumann, H. P. H., Bausch, B., McWhinney, S. R., Bender, B. U., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020152 · Cited by 1,367
Biochemical Diagnosis of Pheochromocytoma: Which Test Is Best?
Lenders, J. W. M., Pacak, K., Walther, M. M., Linehan, W. M., Mannelli, M., Friberg, P., Keiser, H. R., Goldstein, D. S., & Eisenhofer, G. (2002) · JAMA · doi:10.1001/jama.287.11.1427 · Cited by 1,134
Self-citationPeptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Reubi, J. C. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0007 · Cited by 1,131
Management of the clinically inapparent adrenal mass ("incidentaloma")
Grumbach, M. M., Biller, B. M. K., Braunstein, G. D., Campbell, K. K., Carney, J. A., Godley, P. A., Harris, E. L., Lee, J. K. T., Oertel, Y. C., Posner, M. C., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-5-200303040-00013 · Cited by 945 · cited 1×
“Adrenal masses are present in about 5–9% of the general population (21, 22, 116, 117).”
BackgroundIncidentally Discovered Adrenal Masses*
KLOOS, R. T., GROSS, M. D., FRANCIS, I. R., KOROBKIN, M., & SHAPIRO, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-4-460 · Cited by 828
The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors
LAMBERTS, S. W. J., KRENNING, E. P., & REUBI, J.-C. (1991) · Endocrine Reviews · doi:10.1210/edrv-12-4-450 · Cited by 805
Thompson, L. D. R. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200205000-00002 · Cited by 715
Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature
Boland, G. W., Lee, M. J., Gazelle, G. S., Halpern, E. F., McNicholas, M. M., & Mueller, P. R. (1998) · American Journal of Roentgenology · doi:10.2214/ajr.171.1.9648789 · Cited by 693
Adrenal Masses: Characterization with Combined Unenhanced and Delayed Enhanced CT
Caoili, E. M., Korobkin, M., Francis, I. R., Cohan, R. H., Platt, J. F., Dunnick, N. R., & Raghupathi, K. I. (2002) · Radiology · doi:10.1148/radiol.2223010766 · Cited by 690
Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma
Pacak, K., Linehan, W. M., Eisenhofer, G., Walther, M. M., & Goldstein, D. S. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-4-200102200-00016 · Cited by 618
Self-citationScintigraphic Localization of Pheochromocytoma
Sisson, J. C., Frager, M. S., Valk, T. W., Gross, M. D., Swanson, D. P., Wieland, D. M., Tobes, M. C., Beierwaltes, W. H., & Thompson, N. W. (1981) · New England Journal of Medicine · doi:10.1056/nejm198107023050103 · Cited by 544
Pheochromocytoma: State-of-the-Art and Future Prospects
Bravo, E. L., & Tagle, R. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0013 · Cited by 493
Biochemical Diagnosis of Pheochromocytoma: How to Distinguish True- from False-Positive Test Results
Eisenhofer, G., Goldstein, D. S., Walther, M. M., Friberg, P., Lenders, J. W. M., Keiser, H. R., & Pacak, K. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-030005 · Cited by 492
Self-citationClinical Experience Over 48 Years With Pheochromocytoma
Goldstein, R. E., O’Neill, J. A., Holcomb, G. W., Morgan, W. M., Neblett, W. W., Oates, J. A., Brown, N., Nadeau, J., Smith, B., Page, D. L., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199906000-00001 · Cited by 464
Extra-Adrenal Pheochromocytoma
Whalen, R. K., Althausen, A. F., & Daniels, G. H. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37119-7 · Cited by 452
Averbuch, S. D., Steakley, C. S., Young, R. C., Gelmann, E. P., Goldstein, D. S., Stull, R., & Keiser, H. R. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-4-267 · Cited by 427
Krenning, E. P., Bakker, W., Kooij, P. P. M., Breeman, W. A., Oei, H. Y., de Jong, M., Reubi, J. C., Visser, T. J., Bruns, C., & Kwekkeboom, D. J. (1992) · PubMed · Cited by 420
Evolving Concepts in the Pathophysiology, Diagnosis, and Treatment of Pheochromocytoma
BRAVO, E. L. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-3-356 · Cited by 393
CT time-attenuation washout curves of adrenal adenomas and nonadenomas
Korobkin, M., Brodeur, F. J., Francis, I. R., Quint, L. E., Dunnick, N. R., & Londy, F. (1998) · American Journal of Roentgenology · doi:10.2214/ajr.170.3.9490968 · Cited by 386
Differentiation of adrenal adenomas from nonadenomas using CT attenuation values.
Korobkin, M., Brodeur, F. J., Yutzy, G. G., Francis, I. R., Quint, L. E., Dunnick, N. R., & Kazerooni, E. A. (1996) · American Journal of Roentgenology · doi:10.2214/ajr.166.3.8623622 · Cited by 365
State-of-the-Art Adrenal Imaging
Mayo-Smith, W. W., Boland, G. W., Noto, R. B., & Lee, M. J. (2001) · RadioGraphics · doi:10.1148/radiographics.21.4.g01jl21995 · Cited by 359
Benign adrenocortical masses: diagnosis with chemical shift MR imaging.
Mitchell, D. G., Crovello, M., Matteucci, T., Petersen, R. O., & Miettinen, M. M. (1992) · Radiology · doi:10.1148/radiology.185.2.1410337 · Cited by 335
Pheochromocytomas: Detection with18F DOPA Whole-Body PET—Initial Results
Hoegerle, S., Nitzsche, E., Altehoefer, C., Ghanem, N., Manz, T., Brink, I., Reincke, M., Moser, E., & Neumann, H. P. H. (2002) · Radiology · doi:10.1148/radiol.2222010622 · Cited by 325
Safety of magnetic resonance imaging contrast agents
Shellock, F. G., & Kanal, E. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199909)10:3<477::aid-jmri33>3.0.co;2-e · Cited by 321
Imaging of Adrenal Incidentalomas: Current Status
Dunnick, N. R., & Korobkin, M. (2002) · American Journal of Roentgenology · doi:10.2214/ajr.179.3.1790559 · Cited by 307
Pheochromocytomas: Imaging with 2-[Fluorine-18]fluoro-2-deoxy-d-glucose PET
Shulkin, B. L., Thompson, N. W., Shapiro, B., Francis, I. R., & Sisson, J. C. (1999) · Radiology · doi:10.1148/radiology.212.1.r99jl3035 · Cited by 305
Hedeland, H., Östberg, G., & Hökfelt, B. (1968) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1968.tb02445.x · Cited by 287
SOLANKP, K. K., BOMANJI, J., MOYES, J., MATHER, S. J., TRAINER, P. J., & BRITTON, K. E. (1992) · Nuclear Medicine Communications · doi:10.1097/00006231-199207000-00006 · Cited by 276
Kaltsas, G. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.2.895 · Cited by 275
[123I]Metaiodobenzylguanidine and[111In]Octreotide Uptake in Benign and Malignant Pheochromocytomas1
van der Harst, E., de Herder, W. W., Bruining, H. A., Bonjer, H. J., de Krijger, R. R., Lamberts, S. W. J., van de Meiracker, A. H., Boomsma, F., Stijnen, T., Krenning, E. P., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7238 · Cited by 253
Ilias, I., Yu, J., Carrasquillo, J. A., Chen, C. C., Eisenhofer, G., Whatley, M., McElroy, B., & Pacak, K. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030235 · Cited by 241
Self-citationJamar, F., Barone, R., Mathieu, I., Walrand, S., Labar, D., Carlier, P., Camps, J., Schran, H., Chen, T., Smith, M. C., et al. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1117-1 · Cited by 240
Pheochromocytoma in Italy: a multicentric retrospective study
Mannelli, M., Ianni, L., Cilotti, A., & Conti, A. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1410619 · Cited by 228
Breeman, W. A., de Jong, M., Kwekkeboom, D. J., Valkema, R., Bakker, W. H., Kooij, P. P., Visser, T. J., & Krenning, E. P. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100502 · Cited by 226
Nakajo, M., Shapiro, B., Copp, J., Kalff, V., Gross, M. D., Sisson, J. C., & Beierwaltes, W. H. (1983) · PubMed · Cited by 224
Management of Pheochromocytomas in Patients with Multiple Endocrine Neoplasia Type 2 Syndromes
Lairmore, T. C., Ball, D. W., Baylin, S. B., & Wells, S. A. (1993) · Annals of Surgery · doi:10.1097/00000658-199306000-00001 · Cited by 218
Pacak, K., Eisenhofer, G., Carrasquillo, J. A., Chen, C. C., Li, S.-T., & Goldstein, D. S. (2001) · Hypertension · doi:10.1161/01.hyp.38.1.6 · Cited by 216
Self-citationde Jong, M., Breeman, W. A., Bakker, W., Kooij, P. P. M., Bernard, B. F., Hofland, L. J., Visser, T. J., Srinivasan, A., Schmidt, M. A., Erion, J. L., et al. (1998) · PubMed · Cited by 209
Clinical Spectrum and Outcome of Functional Extraadrenal Paraganglioma
O’Riordain, D. S., Young, W. F., Grant, C. S., Carney, J. A., & van Heerden, J. A. (1996) · World Journal of Surgery · doi:10.1007/s002689900139 · Cited by 201
Pheochromocytoma and paraganglioma: comparison of MR imaging with CT and I-131 MIBG scintigraphy.
Quint, L. E., Glazer, G. M., Francis, I. R., Shapiro, B., & Chenevert, T. L. (1987) · Radiology · doi:10.1148/radiology.165.1.3628794 · Cited by 192
Adrenal masses: differentiation with chemical shift, fast low-angle shot MR imaging.
Tsushima, Y., Ishizaka, H., & Matsumoto, M. (1993) · Radiology · doi:10.1148/radiology.186.3.8430178 · Cited by 184
Adrenal masses: evaluation with fast gradient-echo MR imaging and Gd-DTPA-enhanced dynamic studies.
Krestin, G. P., Steinbrich, W., & Friedmann, G. (1989) · Radiology · doi:10.1148/radiology.171.3.2717737 · Cited by 183
Bilbey, J. H., McLoughlin, R. F., Kurkjian, P. S., Wilkins, G. E., Chan, N. H., Schmidt, N., & Singer, J. (1995) · American Journal of Roentgenology · doi:10.2214/ajr.164.3.7863885 · Cited by 168
18F-DOPA positron emission tomography for the detection of glomus tumours
Hoegerle, S., Ghanem, N., Altehoefer, C., Schipper, J., Brink, I., Moser, E., & Neumann, H. P. H. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1115-3 · Cited by 162
Schlumberger, M. J., Gicquel, C., Lumbroso, J., Tenenbaum, F., Comoy, E., Bosq, J., Fonseca, E., Ghillani‐Dalbin, P., Aubert, B., Travagli, J. P., et al. (1992) · Journal of Endocrinological Investigation · doi:10.1007/bf03345807 · Cited by 156
Jalil, N. D., Pattou, F. N., Combemale, F., Chapuis, Y., Henry, J., Peix, J., & Proye, C. A. G. (2002) · The European Journal of Surgery · doi:10.1080/110241598750004913 · Cited by 153
PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma.
Shulkin, B. L., Wieland, D. M., Schwaiger, M., et al. (1992) · PubMed · Cited by 153
Maurea, S., Cuocolo, A., Reynolds, J. C., Tumeh, S. S., Mg, B., Linehan, W. M., Norton, J. A., Walther, M.-C. M., Keiser, H. R., & Neumann, R. D. (1993) · PubMed · Cited by 144
Computed tomography versus ultrasound of the adrenal gland: a prospective study.
Abrams, H. L., Siegelman, S. S., Adams, D. F., Sanders, R. C., Finberg, H. J., Hessel, S. J., & McNeil, B. J. (1982) · Radiology · doi:10.1148/radiology.143.1.7063713 · Cited by 141
Pheochromocytoma: evaluation, diagnosis, and treatment
Walther, M. M., Keiser, H. R., & Linehan, W. M. (1999) · World Journal of Urology · doi:10.1007/s003450050102 · Cited by 141
Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues.
Khafagi, F. A., Shapiro, B., Fig, L. M., Mallette, S., & Sisson, J. C. (1989) · PubMed · Cited by 141
Tenenbaum, F., Lumbroso, J., Schlumberger, M. J., Mure, A., Plouin, P., Caillou, B., & Parmentier, C. (1995) · PubMed · Cited by 139
Differentiation of adrenal masses with MR imaging: comparison of techniques.
Reinig, J. W., Stutley, J. E., Leonhardt, C. M., SPICER, K. M., Margolis, M., & Caldwell, C. B. (1994) · Radiology · doi:10.1148/radiology.192.1.8208962 · Cited by 135
Varghese, J. C., Hahn, P. F., Papanicolaou, N., et al. (1997) · Clinical Radiology · doi:10.1016/s0009-9260(97)80252-8 · Cited by 133
Pheochromocytoma: effect of nonionic contrast medium in CT on circulating catecholamine levels.
Mukherjee, J. J., Peppercorn, P. D., Reznek, R. H., Patel, V., Kaltsas, G., Besser, M., & Grossman, A. B. (1997) · Radiology · doi:10.1148/radiology.202.1.8988215 · Cited by 130
Glowniak, J. V., Kilty, J. E., Amara, S. G., Hoffman, B. J., & Turner, F. E. (1993) · PubMed · Cited by 127
Namimoto, T., Yamashita, Y., Mitsuzaki, K., Nakayama, Y., Makita, O., Kadota, M., & Takahashi, M. (2001) · Radiology · doi:10.1148/radiology.218.3.r01mr15642 · Cited by 125
Adrenal pheochromocytoma: A clinicopathologic review of 60 cases
Medeiros, L. J., Wolf, B. C., Balogh, K., & Federman, M. (1985) · Human Pathology · doi:10.1016/s0046-8177(85)80107-6 · Cited by 124
Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma
Pomares, F. J., Canas, R., Rodriguez, J. M., Hernandez, A. M., Parrilla, P., & Tebar, F. J. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.3751208.x · Cited by 124
Safety of Magnetic Resonance Contrast Media
Runge, V. M. (2001) · Topics in Magnetic Resonance Imaging · doi:10.1097/00002142-200108000-00007 · Cited by 116
Furuta, N., Kiyota, H., Yoshigoe, F., Hasegawa, N., & Ohishi, Y. (1999) · International Journal of Urology · doi:10.1046/j.1442-2042.1999.06310.x · Cited by 114
Chang, A., Glazer, H. S., Lee, J., Ling, D., & Heiken, J. P. (1987) · Radiology · doi:10.1148/radiology.163.1.3823423 · Cited by 108
Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases?
van der Harst, E., Bruining, H. A., Bonjer, H. J., van der Ham, F., Dinjens, W. N. M., Lamberts, S. W. J., de Herder, W. W., Koper, J. W., Stijnen, T., Proye, C. A. G., et al. (2000) · The Journal of Pathology · Cited by 103
Lynn, M. D., Shapiro, B., Sisson, J. C., et al. (1985) · Radiology · doi:10.1148/radiology.155.3.4001380 · Cited by 102
The efficacy of iodine-123-MIBG as a screening test for pheochromocytoma.
Mozley, P. D., Kim, C. K., Mohsin, J., Jatlow, A. D., Gosfield, E., & Alavi, A. A. (1994) · PubMed · Cited by 101
Pheochromocytoma: Study of 50 Cases
Lucón, A. M., Pereira, M. A. A., Mendonca, B. B., Halpern, A., Wajchenbeg, B. L., & Arap, S. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)64925-5 · Cited by 99
How accurate is MR imaging in characterisation of adrenal masses: update of a long-term study
Hönigschnabl, S., Gallo, S., Niederle, B., Prager, G., Kaserer, K., Lechner, G. L., & Heinz‐Peer, G. (2002) · European Journal of Radiology · doi:10.1016/s0720-048x(01)00443-0 · Cited by 98
Epelbaum, J., Bertherat, J. Y., Prevost, G. P., Kordon, C., Meyerhof, W., Wulfsen, I., Richter, D., & Plouin, P. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.6.1837 · Cited by 92
Clinical experience with malignant pheochromocytomas.
Scott, H. W., Reynolds, V., Green, N., Page, D. L., Oates, J. A., Robertson, D., & Roberts, S. (1982) · PubMed · Cited by 91
Maurea, S., Cuocolo, A., Reynolds, J. C., Neumann, R. D., & Salvatore, M. (1996) · PubMed · Cited by 89
O’Brien, T., Young, W. F., Davlla, D. G., Schelthauer, B. W., Kovács, K., Horváth, É., Vale, W. G., & van Heerden, J. A. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02359.x · Cited by 89
Plasma catecholamines in pheochromocytoma: effect of urographic contrast media
Räisänen, J. P., Shapiro, B., Glazer, G. M., et al. (1984) · American Journal of Roentgenology · doi:10.2214/ajr.143.1.43 · Cited by 86
MR Imaging of Pheochromocytomas
Fink, I. J., Reinig, J. W., Dwyer, A. J., et al. (1985) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-198505000-00006 · Cited by 84
van Santen, H. M., de Kraker, J., van Eck‐Smit, B. L. F., de Vijlder, J. J. M., & Vulsma, T. (2002) · Cancer · doi:10.1002/cncr.10447 · Cited by 81
Nuclear medicine imaging of pheochromocytoma and neuroblastoma.
Sisson, J. C., & Shulkin, B. L. (1999) · PubMed · Cited by 79
Malignant pheochromocytoma: A series of 14 cases observed between 1966 and 1990
Mornex, R., Badet, C., & Peyrin, L. (1992) · Journal of Endocrinological Investigation · doi:10.1007/bf03345808 · Cited by 79
Somatostatin receptor subtype expression in human tumors
Hofland, L. J., & Lamberts, S. W. J. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_2.s31 · Cited by 79
Localization of pheochromocytoma: MIBG [correction of MIGB], CT, and MRI correlation.
VELCHIK, M. G., Alavi, A. A., Kressel, H. Y., & Engelman, K. (1989) · PubMed · Cited by 77
Sensitivity of Diagnostic and Localization Tests for Pheochromocytoma in Clinical Practice
Witteles, R. M., Kaplan, E. L., & Roizen, M. F. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.16.2521 · Cited by 75
State-of-the-art MR imaging of the adrenal gland.
Lee, M. J., Mayo-Smith, W. W., Hahn, P. F., Goldberg, M. A., Boland, G. W., Saini, S., & Papanicolaou, N. (1994) · Radiographics · doi:10.1148/radiographics.14.5.7991811 · Cited by 75
Radioisotope diagnosis and therapy of malignant pheochromocytoma
Shapiro, B., Gross, M. D., & Shulkin, B. L. (2001) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(01)00492-1 · Cited by 74
Berglund, A. S., Hulthén, U. L., Manhem, P., Thorsson, O., Wollmer, P., & Törnquist, C. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00792.x · Cited by 71
Proye, C., Vix, M., Goropoulos, A., Kerlo, P., & Lecomte-Houcke, M. (1992) · Journal of Endocrinological Investigation · doi:10.1007/bf03345810 · Cited by 70
Kopf, D., Bockisch, A., Steinert, H. C., Hahn, K. M., Beyer, J., Neumann, H. P. H., Hensen, J., & Lehnert, H. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.d01-1738.x · Cited by 69
Role of venous sampling in locating a phaeochromocytoma.
Allison, D. J., Mj, B., Jones, D. H., & Timmis, J. B. (1983) · BMJ · doi:10.1136/bmj.286.6371.1122 · Cited by 66
Biochemical Diagnosis of Pheochromocytoma—Is it Time to Switch to Plasma-Free Metanephrines?
Eisenhofer, G. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021913 · Cited by 63
Pheochromocytoma and pregnancy: the epitome of high risk.
Freier, D. T., & Thompson, N. W. (1993) · PubMed · Cited by 62
Paraganglioma as a systemic syndrome: pitfalls and strategies
Maier, W., Marangos, N., & Laszig, R. (1999) · The Journal of Laryngology & Otology · doi:10.1017/s0022215100145761 · Cited by 61
Primary Extra-Adrenal Pheochromocytoma Positive I-123 MIBG Imaging with Negative I-131 MIBG Imaging
Shulkin, B. L., Shapiro, B., Francis, I. R., Dorr, R. P., SHEN, S.-W., & Sisson, J. C. (1986) · Clinical Nuclear Medicine · doi:10.1097/00003072-198612000-00012 · Cited by 60
A "Pheo" Lurks: Novel Approaches for Locating Occult Pheochromocytoma
Pacák, K., Goldstein, D. S., Doppman, J. L., Shulkin, B. L., Udelsman, R., & Eisenhofer, G. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7714 · Cited by 59
MR evaluation of adrenal masses at 1.5 T
Baker, M. E., Blinder, R., Spritzer, C. E., Leight, G. S., Herfkens, R. J., & Dunnick, N. R. (1989) · American Journal of Roentgenology · doi:10.2214/ajr.153.2.307 · Cited by 57
Comparison of adrenal and extraadrenal pheochromocytomas.
Pommier, R. F., Vetto, J. T., Billingsly, K., Woltering, E. A., & Brennan, M. F. (1993) · PubMed · Cited by 57
Ramachandran, B., Houben, K. F., Rozenberg, Y. Y., Haigh, J. R., Varpetian, A., & Howard, B. D. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80469-4 · Cited by 56
Adrenal Incidentaloma—A Modern Disease with Old Complications
Angeli, A., & Terzolo, M. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021436 · Cited by 51
1-123 MIBG Scintigraphy in Adults: A Report of Clinical Experience
Elgazzar, A. H., Gelfand, M. J., Washburn, L. C., Clark, J., NAGARAJ, N., Cummings, D. D., Hughes, J. P., & Maxon, H. R. (1995) · Clinical Nuclear Medicine · doi:10.1097/00003072-199502000-00011 · Cited by 50
State-of-the-art CT and MRI of the adrenal gland
Peppercorn, P. D., & Reznek, R. H. (1997) · European Radiology · doi:10.1007/s003300050214 · Cited by 47
Salivary gland accumulation of meta-[131I]iodobenzylguanidine.
Nakajo, M., Shapiro, B., Sisson, J. C., Swanson, D. P., & Beierwaltes, W. H. (1984) · PubMed · Cited by 45
Nuclear Medicine Applications for Neuroendocrine Tumors
Chatal, J., Bodic, M. F. L., Kraeber‐Bodéré, F., Rousseau, C., & Resche, I. (2000) · World Journal of Surgery · doi:10.1007/s002680010213 · Cited by 44
Maurea, S., Klain, M., Caracò, C., Ziviello, M., & Salvatore, M. (2002) · Nuclear Medicine Communications · doi:10.1097/00006231-200210000-00004 · Cited by 37
Prager, G., Heinz‐Peer, G., Passler, C., Kaczirek, K., Schindl, M., Scheuba, C., Vierhapper, H., & Niederle, B. (2002) · World Journal of Surgery · doi:10.1007/s00268-002-6625-9 · Cited by 32
Brans, B., Monsieurs, M. A., Laureys, G., Kaufman, J.-M., Thierens, H., & Dierckx, R. A. J. O. (2001) · Medical and Pediatric Oncology · doi:10.1002/mpo.1261 · Cited by 30
Adrenal medulla and extra-adrenal paraganglia
Oudijk, L., de Krijger, R. R., Pacák, K., & Tischler, A. S. (2000) · Cited by 29
Localization of carcinoids and pheochromocytomas with vein catheterization and amine determination
Nobin, A., Karp, W., Lunderquist, A., Rosengren, E., Sandén, G., & Sundler, F. (1982) · Brain Research Bulletin · doi:10.1016/0361-9230(82)90186-1 · Cited by 28
Functioning Thoracic Paraganglioma: Association with Von Hippel-Lindau Syndrome
Bender, B., Altehöfer, C., Januszewicz, A., Gärtner, R., Schmidt, H., Hoffmann, M. M., Heidemann, P. H., & Neumann, H. P. H. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.10.3356 · Cited by 26
The use of venous catheterization in the diagnosis and localization of bilateral phaeochromocytomas
Newbould, E., Ross, G. A., Dacle, J. E., Bouloux, P. M., BESSER, G. M., & Grossman, A. B. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb03496.x · Cited by 26
Lenders, J. W. M., Willemsen, J. J., Beissel, T., KLOPPENBORG, P. W. C., Thien, T. A., & Benraad, T. J. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90105-k · Cited by 25
Malignant Pheochromocytoma, Still a Therapeutic Challenge
Tato, A., Orte, L., Diz, P., Quereda, C., & Ortuno, J. (1997) · American Journal of Hypertension · doi:10.1016/s0895-7061(97)00064-2 · Cited by 24
Tsuchimochi, S., Nakajo, M., Nakabeppu, Y., et al. (1997) · Clinical Nuclear Medicine · doi:10.1097/00003072-199710000-00005 · Cited by 21
123 I-MIBG scintigraphy of catecholamine systems: impediments to applications in clinical medicine
Eisenhofer, G. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590000263 · Cited by 20
Brain Uptake of lodine-131 Metaiodobenzylguanidine Following Therapy of Malignant Pheochromocytoma
Dwamena, B. A., Zempel, S., Klopper, J. F., van Heerden, B., WIELAND, D., & Shapiro, B. (1998) · Clinical Nuclear Medicine · doi:10.1097/00003072-199807000-00009 · Cited by 19
Metabolic fate of injected radiolabelled dopamine and 2-fluorodopamine in rats
HOLMES, C., Hovevey-Sion, D., ELSENHOFER, G., Kopin, I. J., KIRK, K., CHANG, P., Szemeredi, K., & GOLDSTEIN, D. (1990) · Neuropharmacology · doi:10.1016/0028-3908(90)90137-g · Cited by 15
Imaging of the Endocrine System
Aslam, S., Sohaib, A., Rockall, A., Bomanji, J. B., Evanson, J., & Reznek, R. H. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-10163-2.50074-9 · Cited by 15
ADRENAL, PANCREATIC, AND SCROTAL ULTRASOUND IN ENDOCRINE DISEASE
Gooding, G. A. W. (1993) · Radiologic Clinics of North America · doi:10.1016/s0033-8389(22)00357-8 · Cited by 12
Tytgat, G. A. M., den Brug, M. D.-V., Voûte, P. A., Smets, L. A., & Rutgers, M. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(02)00804-4 · Cited by 10
Multiple venous sampling for catecholamine assay in the diagnosis of malignant pheochromocytoma
Pontremoli, R., Borgonovo, G., Ranise, A., & Garibotto, G. (1989) · Journal of Endocrinological Investigation · doi:10.1007/bf03350026 · Cited by 4
Cited by
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,824
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Authors/Task Force Members:, Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehm236 · Cited by 2,384
Lenders, J. W., Eisenhofer, G., Mannelli, M., & Pacak, K. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67139-5 · Cited by 1,524
Self-citation
Metadata
- Authors
- Ilias, I., & Pacak, K.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-02
- Volume
- 89
- Issue
- 2
- Pages
- 479-491
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2022313726
- Cited by
- 332
- References
- 116
- FWCI
- 24.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.